journal
https://read.qxmd.com/read/38126339/patterns-of-radiological-response-to-tebentafusp-in-patients-with-metastatic-uveal-melanoma
#21
JOURNAL ARTICLE
Natalia M Roshardt Prieto, Patrick Turko, Caroline Zellweger, Thi Dan Linh Nguyen-Kim, Ramon Staeger, Elisa Bellini, Mitchell P Levesque, Reinhard Dummer, Egle Ramelyte
Metastatic uveal melanoma (mUM) is a rare type of melanoma with poor outcomes. The first systemic treatment to significantly prolong overall survival (OS) in patients with mUM was tebentafusp, a bispecific protein that can redirect T-cells to gp-100 positive cells. However, the objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) may underestimate the clinical impact of tebentafusp. As metabolic response assessed by PET Response Criteria in Solid Tumors (PERCIST) has been reported to better correlate with clinical outcome, we here compared the patterns of radiological and morphological responses in HLA-A*02:01-positive patients with mUM treated with tebentafusp...
December 19, 2023: Melanoma Research
https://read.qxmd.com/read/38092017/development-and-validation-of-a-nomogram-for-elderly-patients-with-ulcerative-melanoma
#22
JOURNAL ARTICLE
Jie Yan, Haiyan Wang, Xiaoou Lu, Fengjuan Li
The current state of survival prediction models for elderly patients with ulcerative melanoma (uCM) is limited. We sought to develop a nomogram model that can predict overall survival of geriatric patients with uCM. The Surveillance, Epidemiology, and End Results (SEER) database served as a source for patients diagnosed with uCM between 2004 and 2015. Statistical analyses were conducted to determine the significant prognostic elements affecting overall survival using multivariate and univariate Cox proportional risk regression models...
December 13, 2023: Melanoma Research
https://read.qxmd.com/read/38092014/real-world-management-practices-and-characteristics-of-patients-with-advanced-melanoma-initiated-on-immuno-oncology-or-targeted-therapy-in-the-first-line-setting-during-the-period-2015-2018-in-greece-the-summer-study-a-retrospective-multicenter-chart-review
#23
JOURNAL ARTICLE
Dimitrios Bafaloukos, Panagiotis Kouzis, Panagiotis Gouveris, Ioannis Boukovinas, Konstantinos Kalbakis, Sofia Baka, Georgios Kyriakakis, Despoina Moschou, Aristea Molfeta, Stamatia Demiri, Dimitrios Mavroudis, Spanoudi Filio, Ioannis Dimitriadis, Helen Gogas
This study primarily aimed to generate real-world evidence (RWE) on the profile and first-line treatment (1LT) patterns of patients with advanced (unresectable Stage III/metastatic) cutaneous melanoma initiated on immuno-oncology (IO)- or targeted therapy (TT)-based 1LT between 1 January 2015 and 1 January 2018 (index period), in routine settings of Greece. This was a multicenter, retrospective chart review study. Eligible consented (unless deceased, for whom consent was waived by the hospital) patients were consecutively included by six oncology clinics...
December 13, 2023: Melanoma Research
https://read.qxmd.com/read/38092013/dabrafenib-plus-trametinib-in-unselected-advanced-braf-v600-mut-melanoma-a-non-interventional-multicenter-prospective-trial
#24
JOURNAL ARTICLE
Erika Richtig, Van A Nguyen, Peter Koelblinger, Ingrid Wolf, Helmut Kehrer, Werner Saxinger, Julia M Ressler, Georg Weinlich, Damian Meyersburg, Christine Hafner, Elisabeth Jecel-Grill, Julian Kofler, Bernhard Lange-Asschenfeldt, Felix Weihsengruber, Klemens Rappersberger, Nina Svastics, Klaus Gasser, Arno Seeber, Franz Kratochvill, Sophie Nagler, Bernhard Mraz, Christoph Hoeller
OBJECTIVE: The efficacy of combined BRAF and MEK inhibition for BRAF V600-mutant melanoma in a broad patient population, including subgroups excluded from phase 3 trials, remains unanswered. This noninterventional study (DATUM-NIS) assessed the real-world efficacy, safety and tolerability of dabrafenib plus trametinib in Austrian patients with unresectable/metastatic melanoma. METHODS: This multicenter, open-label, non-interventional, post-approval, observational study investigated the effectiveness of dabrafenib plus trametinib prescribed in day-to-day clinical practice to patients (N = 79) with BRAF V600-mutant unresectable/metastatic melanoma with M1c disease (American Joint Committee on Cancer staging manual version 7), ECOG > 1, and elevated serum lactate dehydrogenase (LDH)...
December 13, 2023: Melanoma Research
https://read.qxmd.com/read/38051781/targeting-beta-adrenergic-receptor-pathways-in-melanoma-how-stress-modulates-oncogenic-immunity
#25
JOURNAL ARTICLE
Benjamin Switzer, Igor Puzanov, Shipra Gandhi, Elizabeth A Repasky
The intricate pathways of the sympathetic nervous system hold an inherently protective role in the setting of acute stress. This is achieved through dynamic immunomodulatory and neurobiological networks. However, excessive and chronic exposure to these stress-induced stimuli appears to cause physiologic dysfunction through several mechanisms that may impair psychosocial, neurologic, and immunologic health. Numerous preclinical observations have identified the beta-2 adrenergic receptor (β2-AR) subtype to possess the strongest impact on immune dysfunction in the setting of chronic stressful stimuli...
December 4, 2023: Melanoma Research
https://read.qxmd.com/read/38051786/quality-of-life-after-melphalan-percutaneous-hepatic-perfusion-for-patients-with-metastatic-uveal-melanoma
#26
JOURNAL ARTICLE
Ganesh Vigneswaran, Weeratunge Malalasekera, Victoria Smith, Tom Gibson, Shian Patel, Matthew Wheater, Ioannis Karydis, Sanjay Gupta, Brian Stedman, Sachin Modi
BACKGROUND: Recent studies indicate that melphalan percutaneous hepatic perfusion (M-PHP) for liver metastases from ocular melanoma (mUM) improves survival. Importantly, this benefit must be carefully balanced with changes in a patient's quality of life (QoL). This study examines the QoL changes post-M-PHP. METHODS: Retrospective analysis of the change in QoL using the Functional Assessment of Cancer Therapy-General (FACT-G) with mUM patients receiving M-PHP (n = 20)...
December 1, 2023: Melanoma Research
https://read.qxmd.com/read/37890184/first-time-office-visit-for-suspicious-skin-lesion-evaluation-as-a-predictor-of-high-risk-melanoma
#27
JOURNAL ARTICLE
Rose Parisi, Hemali Shah, Emily Everdell, Paul Feustel, Lindy Davis
No abstract text is available yet for this article.
December 1, 2023: Melanoma Research
https://read.qxmd.com/read/37890183/vitiligo-like-hypopigmentation-induced-by-dabrafenib-trametinib-a-potential-marker-for-clinical-response
#28
JOURNAL ARTICLE
Elena Carmona-Rocha, Ivana Sullivan, Oriol Yélamos
No abstract text is available yet for this article.
December 1, 2023: Melanoma Research
https://read.qxmd.com/read/37890182/pstat5-is-associated-with-improved-survival-in-patients-with-thick-or-ulcerated-primary-cutaneous-melanoma
#29
JOURNAL ARTICLE
Samuel X Tan, Sharene Chong, Casey Rowe, Magdalena Claeson, James Dight, Chenhao Zhou, Mathieu P Rodero, Maryrose Malt, B Mark Smithers, Adele C Green, Kiarash Khosrotehrani
Identifying prognostic biomarkers to predict clinical outcomes in stage I and II cutaneous melanomas could guide the clinical application of adjuvant and neoadjuvant therapies. We aimed to investigate the prognostic value of phosphorylated signal transducer and activator of transcription 5 (pSTAT5) as a biomarker in early-stage melanoma. This study evaluated all initially staged Ib and II melanoma patients undergoing sentinel node biopsy at a tertiary centre in Brisbane, Australia between 1994 and 2007, with survival data collected from the Queensland Cancer Registry...
December 1, 2023: Melanoma Research
https://read.qxmd.com/read/38016155/small-vessel-vasculitis-leading-to-severe-acute-kidney-injury-after-ipilimumab-a-case-report
#30
JOURNAL ARTICLE
Rui Duarte, Filipa Trigo, Ivan Luz, Paulo Santos
Immune checkpoint inhibitors are effective monoclonal antibodies used in cancer treatment, particularly in metastatic melanoma. They target proteins responsible for cancer cells evading the immune system. However, their use can lead to immune-related adverse events, with the skin and gastrointestinal tract being commonly affected. Kidney involvement is rarer, with interstitial nephritis being the most common manifestation. In a unique case, kidney biopsy-proven small-vessel vasculitis with arteriolar immune deposition was observed following ipilimumab administration...
November 28, 2023: Melanoma Research
https://read.qxmd.com/read/38016153/real-world-relapse-free-survival-data-on-adjuvant-anti-pd-1-therapy-for-patients-with-newly-diagnosed-and-recurrent-stage-iii-melanoma
#31
JOURNAL ARTICLE
Emma H A Stahlie, Lisanne P Zijlker, Michel W J M Wouters, Yvonne M Schrage, Winan J van Houdt, Alexander C J van Akkooi
We aimed to compare the relapse-free survival (RFS) in patients treated with adjuvant anti-programmed cell death-1 (anti-PD-1) therapy for a first diagnosis of stage III melanoma to patients treated after resection of the recurrences. Patients treated with adjuvant anti-PD-1 therapy after complete resection of stage III melanoma between September 2018 and January 2021, were included. Depending on when adjuvant anti-PD-1 treatment was initiated, patients were divided over 2 cohorts: for the first diagnosis (cohort A) or for a second or subsequent diagnosis (cohort B) of stage III melanoma...
November 28, 2023: Melanoma Research
https://read.qxmd.com/read/37962233/tumour-regression-predicts-better-response-to-interferon-therapy-in-melanoma-patients-a-retrospective-single-centre-study
#32
JOURNAL ARTICLE
Noémi E Mezőlaki, Eszter Baltás, Henriette L Ócsai, Anita Varga, Irma Korom, Erika Varga, István B Németh, Erika G Kis, János Varga, Ádám Kocsis, Rolland Gyulai, Mátyás Bukva, Lajos Kemény, Judit Oláh
We hypothesise that regression may have an impact on the effectiveness of adjuvant IFN therapy, based on its role in the host immune response. Our purpose is to investigate regression and ulceration as prognostic factors in case of interferon-alpha (IFN)-treated melanoma patients. We followed 357 IFN-treated melanoma patients retrospectively, investigating progression-free survival (PFS) and overall survival (OS) depending on the presence of ulceration and regression. A Kaplan-Meier analysis was performed, and we used a Cox regression analysis to relate risk factors...
November 13, 2023: Melanoma Research
https://read.qxmd.com/read/37962220/effectiveness-safety-and-utilization-of-cobimetinib-and-vemurafenib-in-patients-with-braf-v600-mutant-melanoma-with-and-without-cerebral-metastasis-under-real-world-conditions-in-germany-the-non-interventional-study-covenis
#33
JOURNAL ARTICLE
Katharina C Kähler, Dirk Debus, Gaston Schley, Daniela Göppner, Jessica C Hassel, Friedegund Meier, Patrick Terheyden, Rudolf Stadler, Thomas Tüting, Martin Kaatz, Norman-Philipp Hoff, Ehsan Masoudi, Agnieszka Zdanowicz-Specht, Minh Tam Nguyen, Peter Mohr
Cobimetinib/vemurafenib combination therapy is approved for treatment of adults with unresectable or metastatic BRAF V600 mutated malignant melanoma (mM). The non-interventional post-authorisation safety study coveNIS collected real-world data on cobimetinib/vemurafenib treatment focussing on overall survival (OS), safety and utilization. MM patients with brain metastases are usually excluded from clinical studies. coveNIS observed 2 cohorts: mM patients without (Cohort A) and with cerebral metastases (Cohort B), aiming to close the data gap for the latter population...
November 13, 2023: Melanoma Research
https://read.qxmd.com/read/37939076/bone-marrow-metastases-a-systematic-review-of-a-neglected-involvement-in-malignant-melanoma
#34
JOURNAL ARTICLE
Giovanni Paolino, Andrea Carugno, Franco Rongioletti, Maurilio Ponzoni, Vincenzo Russo, Paolo Sena, Marco Ardigò, Antonio Costanzo, Santo Raffaele Mercuri, Mario Valenti
The occurrence of bone marrow metastases (BMM) in melanoma patients is often underestimated, with only 7% detected during in-vivo staging procedures but rising to 45% in autopsy cases. This systematic review aims to shed light on the clinical and laboratory features of BMM in melanoma by analyzing 73 studies selected from 2 482 initially retrieved from PubMed, Embase, and Cochrane CENTRAL databases. Our findings reveal a slight male predominance, with a median age at BMM diagnosis of 56 years...
November 8, 2023: Melanoma Research
https://read.qxmd.com/read/37939058/management-of-metastatic-bone-disease-of-melanoma
#35
JOURNAL ARTICLE
Wenyan Chen, Chen Yang, Biqi Chen, Mian Xi, Baoqing Chen, Qiaoqiao Li
One of the most aggressive tumors arising from the skin, mucosa, and uvea is malignant melanoma, which easily metastasizes. Bone tissue is one of the most typical locations for distant metastasis, and around 5%-20% of patients eventually acquired skeletal metastases. For decades, the incidence of bone metastases was higher, bringing greater burden on the family, society, and healthcare system owing to the progress of targeted therapy and immunotherapy, which prolonging the survival time substantially. Moreover, bone metastases result in skeletal-related events, which influence the quality of life, obviously...
November 8, 2023: Melanoma Research
https://read.qxmd.com/read/37924530/prognosis-of-cdkn2a-germline-mutation-in-patients-with-familial-melanoma-a-systematic-review-and-meta-analysis
#36
JOURNAL ARTICLE
Ana Taibo, Sabela Paradela, Jorge Suanzes-Hernández, Vanesa Balboa-Barreiro, Javier Amado-Bouza, Eduardo Fonseca
Familial melanoma is defined as melanoma occurring in two or more first-degree relatives by the WHO. Germline mutations are isolated in a subset of them. It is well known that CDKN2A is the most frequently mutated high-risk gene in familial melanoma, however, the prognosis it confers to patients who carry its mutations is still controversial. This review aims to assess whether germline mutations imply a worse prognosis in patients with familial melanoma. A systematic review and meta-analysis were conducted by searching the electronic databases PubMed/MEDLINE, EMBASE, and Cochrane Library...
November 2, 2023: Melanoma Research
https://read.qxmd.com/read/37924529/intratumoural-and-systemic-inflammation-as-predictors-for-treatment-response-in-braf-mutated-melanoma-patients-under-targeted-therapies
#37
JOURNAL ARTICLE
Thilo Gambichler, Maria Iordanou, Jürgen C Becker, Laura Susok
Intratumoural as well as systemic inflammation in melanoma has thoroughly been studied in the context of patients treated with immune checkpoint inhibitors but not with BRAF/MEK inhibitors (BRAFi/MEKi). We aimed to study whether parameters of intratumoral and systemic inflammation correlate with clinical outcome in patients with BRAF-mutant metastatic melanoma treated with BRAFi/MEKi. We studied 51 CM patients with unresectable stage III or IV who had the indication for BRAFi/MEKi treatment based on confirmed BRAF mutation...
November 2, 2023: Melanoma Research
https://read.qxmd.com/read/37924528/correlations-between-inflammatory-cytokine-levels-and-degree-of-pigmentation-in-acral-melanomas
#38
JOURNAL ARTICLE
Hong Euy Kim, Jinkyeong Kim, Hyung Keon Park, Jee-Bum Lee, Sook Jung Yun
Cutaneous melanoma, a highly aggressive skin tumor, is characterized by complex signaling pathways in terms of its pathogenesis and progression. Although the degree of pigmentation in melanoma determines its progression, metastasis, and prognosis, its association with inflammatory cytokines remains unclear. Thus, we evaluated the associations between melanoma pigmentation and plasma levels of inflammatory cytokines; furthermore, we investigated the potential variations in this relationship across the primary anatomic sites of melanoma...
November 2, 2023: Melanoma Research
https://read.qxmd.com/read/37924527/impact-of-anesthesia-choice-in-cutaneous-melanoma-surgery
#39
JOURNAL ARTICLE
Matthew G K Benesch, Joseph J Skitzki
Invasive cutaneous melanoma is the most lethal skin cancer, but fortunately, the vast majority can be surgically treated with wide local excision, and sometimes additionally with sentinel or index lymph node biopsy for prognostication. Melanomas are particularly immunogenic malignancies, and preclinical studies have demonstrated that use of volatile anesthetics and opioids, unlike local agents, can suppress the immune system during the perioperative period. Immunosuppression has implications for creating a potentially favorable microenvironment for the survival and propagation of residual melanoma cells or micro-metastases, which could lead to disease relapse, both in the local tumor bed and distally...
November 2, 2023: Melanoma Research
https://read.qxmd.com/read/37924526/melanomas-and-mast-cells-an-ambiguous-relationship
#40
JOURNAL ARTICLE
Lisa M Kohl, Tina L Sumpter
Mast cells (MCs) accumulate in a broad range of tumors, including melanomas. While MCs are potent initiators of immunity in infection, and in allergic inflammation, the function of MCs in anti-melanoma immunity is unclear. MCs have the potential to release tumoricidal cytokines and proteases, to activate antigen-presenting cells and to promote anti-tumor adaptive immunity. However, within the immunosuppressive tumor microenvironment (TME), MC activation may promote angiogenesis and contribute to tumor growth...
November 2, 2023: Melanoma Research
journal
journal
30785
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.